CVS HEALTH CORP (CVS) Fundamental Analysis & Valuation
NYSE:CVS • US1266501006
Current stock price
76.13 USD
+0.06 (+0.08%)
At close:
76.25 USD
+0.12 (+0.16%)
After Hours:
This CVS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CVS Profitability Analysis
1.1 Basic Checks
- CVS had positive earnings in the past year.
- In the past year CVS had a positive cash flow from operations.
- Each year in the past 5 years CVS has been profitable.
- Each year in the past 5 years CVS had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of CVS (0.70%) is comparable to the rest of the industry.
- Looking at the Return On Equity, with a value of 2.35%, CVS is in line with its industry, outperforming 57.43% of the companies in the same industry.
- CVS has a Return On Invested Capital (4.90%) which is in line with its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for CVS is below the industry average of 8.98%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.7% | ||
| ROE | 2.35% | ||
| ROIC | 4.9% |
ROA(3y)1.95%
ROA(5y)2.24%
ROE(3y)6.46%
ROE(5y)7.21%
ROIC(3y)5.46%
ROIC(5y)6.31%
1.3 Margins
- CVS has a Profit Margin of 0.44%. This is comparable to the rest of the industry: CVS outperforms 50.49% of its industry peers.
- CVS's Profit Margin has declined in the last couple of years.
- CVS has a Operating Margin (2.58%) which is comparable to the rest of the industry.
- In the last couple of years the Operating Margin of CVS has declined.
- CVS's Gross Margin of 13.77% is on the low side compared to the rest of the industry. CVS is outperformed by 66.34% of its industry peers.
- CVS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.58% | ||
| PM (TTM) | 0.44% | ||
| GM | 13.77% |
OM growth 3Y-19.74%
OM growth 5Y-12.87%
PM growth 3Y-30.97%
PM growth 5Y-30.29%
GM growth 3Y-6.6%
GM growth 5Y-5.48%
2. CVS Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CVS is destroying value.
- Compared to 1 year ago, CVS has more shares outstanding
- CVS has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, CVS has an improved debt to assets ratio.
2.2 Solvency
- CVS has an Altman-Z score of 2.32. This is not the best score and indicates that CVS is in the grey zone with still only limited risk for bankruptcy at the moment.
- The Altman-Z score of CVS (2.32) is comparable to the rest of the industry.
- The Debt to FCF ratio of CVS is 8.27, which is on the high side as it means it would take CVS, 8.27 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of CVS (8.27) is comparable to the rest of the industry.
- CVS has a Debt/Equity ratio of 0.80. This is a neutral value indicating CVS is somewhat dependend on debt financing.
- CVS has a Debt to Equity ratio of 0.80. This is comparable to the rest of the industry: CVS outperforms 48.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 8.27 | ||
| Altman-Z | 2.32 |
ROIC/WACC0.64
WACC7.67%
2.3 Liquidity
- A Current Ratio of 0.84 indicates that CVS may have some problems paying its short term obligations.
- With a Current ratio value of 0.84, CVS is not doing good in the industry: 81.19% of the companies in the same industry are doing better.
- A Quick Ratio of 0.63 indicates that CVS may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.63, CVS is doing worse than 81.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.63 |
3. CVS Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 24.54% over the past year.
- CVS shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -2.11% yearly.
- CVS shows a small growth in Revenue. In the last year, the Revenue has grown by 7.85%.
- CVS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.39% yearly.
EPS 1Y (TTM)24.54%
EPS 3Y-8.11%
EPS 5Y-2.11%
EPS Q2Q%-8.4%
Revenue 1Y (TTM)7.85%
Revenue growth 3Y7.63%
Revenue growth 5Y8.39%
Sales Q2Q%8.17%
3.2 Future
- The Earnings Per Share is expected to grow by 10.88% on average over the next years. This is quite good.
- The Revenue is expected to grow by 4.08% on average over the next years.
EPS Next Y7.45%
EPS Next 2Y10.69%
EPS Next 3Y12.48%
EPS Next 5Y10.88%
Revenue Next Year1.4%
Revenue Next 2Y2.97%
Revenue Next 3Y3.58%
Revenue Next 5Y4.08%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CVS Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 11.28, the valuation of CVS can be described as reasonable.
- Based on the Price/Earnings ratio, CVS is valued cheaply inside the industry as 89.11% of the companies are valued more expensively.
- CVS is valuated cheaply when we compare the Price/Earnings ratio to 25.70, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 10.50, the valuation of CVS can be described as very reasonable.
- Based on the Price/Forward Earnings ratio, CVS is valued cheaply inside the industry as 88.12% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 23.84. CVS is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.28 | ||
| Fwd PE | 10.5 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, CVS is valued a bit cheaper than 77.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.41 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CVS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as CVS's earnings are expected to grow with 12.48% in the coming years.
PEG (NY)1.51
PEG (5Y)N/A
EPS Next 2Y10.69%
EPS Next 3Y12.48%
5. CVS Dividend Analysis
5.1 Amount
- CVS has a Yearly Dividend Yield of 3.50%.
- CVS's Dividend Yield is rather good when compared to the industry average which is at 0.49. CVS pays more dividend than 97.03% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.82, CVS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.5% |
5.2 History
- The dividend of CVS has a limited annual growth rate of 5.96%.
- CVS has paid a dividend for at least 10 years, which is a reliable track record.
- CVS has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.96%
Div Incr Years3
Div Non Decr Years28
5.3 Sustainability
- 192.14% of the earnings are spent on dividend by CVS. This is not a sustainable payout ratio.
- The dividend of CVS is growing, but earnings are growing more, so the dividend growth is sustainable.
DP192.14%
EPS Next 2Y10.69%
EPS Next 3Y12.48%
CVS Fundamentals: All Metrics, Ratios and Statistics
76.13
+0.06 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-10 2026-02-10/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners90.76%
Inst Owner Change3.39%
Ins Owners0.98%
Ins Owner Change-0.81%
Market Cap96.85B
Revenue(TTM)402.07B
Net Income(TTM)1.77B
Analysts79.39
Price Target95.74 (25.76%)
Short Float %1.32%
Short Ratio1.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.5% |
Yearly Dividend2.68
Dividend Growth(5Y)5.96%
DP192.14%
Div Incr Years3
Div Non Decr Years28
Ex-Date01-22 2026-01-22 (0.665)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.24%
Min EPS beat(2)8.8%
Max EPS beat(2)15.69%
EPS beat(4)4
Avg EPS beat(4)19.56%
Min EPS beat(4)8.8%
Max EPS beat(4)30.76%
EPS beat(8)6
Avg EPS beat(8)7.29%
EPS beat(12)10
Avg EPS beat(12)6.2%
EPS beat(16)14
Avg EPS beat(16)5.76%
Revenue beat(2)2
Avg Revenue beat(2)2.03%
Min Revenue beat(2)1.02%
Max Revenue beat(2)3.04%
Revenue beat(4)4
Avg Revenue beat(4)1.93%
Min Revenue beat(4)0.02%
Max Revenue beat(4)3.64%
Revenue beat(8)5
Avg Revenue beat(8)0.75%
Revenue beat(12)9
Avg Revenue beat(12)1.31%
Revenue beat(16)13
Avg Revenue beat(16)2.17%
PT rev (1m)0.08%
PT rev (3m)3.53%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)-4.98%
EPS NY rev (1m)0.16%
EPS NY rev (3m)0.47%
Revenue NQ rev (1m)-1.61%
Revenue NQ rev (3m)-4.36%
Revenue NY rev (1m)-1.18%
Revenue NY rev (3m)-3.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.28 | ||
| Fwd PE | 10.5 | ||
| P/S | 0.24 | ||
| P/FCF | 12.41 | ||
| P/OCF | 9.1 | ||
| P/B | 1.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)6.75
EY8.87%
EPS(NY)7.25
Fwd EY9.53%
FCF(TTM)6.14
FCFY8.06%
OCF(TTM)8.36
OCFY10.98%
SpS316.04
BVpS59.12
TBVpS-28.12
PEG (NY)1.51
PEG (5Y)N/A
Graham Number94.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.7% | ||
| ROE | 2.35% | ||
| ROCE | 6.3% | ||
| ROIC | 4.9% | ||
| ROICexc | 5.23% | ||
| ROICexgc | 18.66% | ||
| OM | 2.58% | ||
| PM (TTM) | 0.44% | ||
| GM | 13.77% | ||
| FCFM | 1.94% |
ROA(3y)1.95%
ROA(5y)2.24%
ROE(3y)6.46%
ROE(5y)7.21%
ROIC(3y)5.46%
ROIC(5y)6.31%
ROICexc(3y)5.85%
ROICexc(5y)6.83%
ROICexgc(3y)22.7%
ROICexgc(5y)25.24%
ROCE(3y)7.06%
ROCE(5y)8.13%
ROICexgc growth 3Y-15.72%
ROICexgc growth 5Y-3.91%
ROICexc growth 3Y-15.74%
ROICexc growth 5Y-5.12%
OM growth 3Y-19.74%
OM growth 5Y-12.87%
PM growth 3Y-30.97%
PM growth 5Y-30.29%
GM growth 3Y-6.6%
GM growth 5Y-5.48%
F-Score6
Asset Turnover1.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 8.27 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 0.7% | ||
| Interest Coverage | -3.47 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 441.57% | ||
| Current Ratio | 0.84 | ||
| Quick Ratio | 0.63 | ||
| Altman-Z | 2.32 |
F-Score6
WACC7.67%
ROIC/WACC0.64
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.77%
Cap/Sales(5y)0.8%
Profit Quality(3y)234.42%
Profit Quality(5y)242.41%
High Growth Momentum
Growth
EPS 1Y (TTM)24.54%
EPS 3Y-8.11%
EPS 5Y-2.11%
EPS Q2Q%-8.4%
EPS Next Y7.45%
EPS Next 2Y10.69%
EPS Next 3Y12.48%
EPS Next 5Y10.88%
Revenue 1Y (TTM)7.85%
Revenue growth 3Y7.63%
Revenue growth 5Y8.39%
Sales Q2Q%8.17%
Revenue Next Year1.4%
Revenue Next 2Y2.97%
Revenue Next 3Y3.58%
Revenue Next 5Y4.08%
EBIT growth 1Y6.02%
EBIT growth 3Y-13.61%
EBIT growth 5Y-5.55%
EBIT Next Year24.52%
EBIT Next 3Y15.26%
EBIT Next 5YN/A
FCF growth 1Y23.41%
FCF growth 3Y-16.58%
FCF growth 5Y-10.28%
OCF growth 1Y16.82%
OCF growth 3Y-13.04%
OCF growth 5Y-7.68%
CVS HEALTH CORP / CVS Fundamental Analysis FAQ
What is the fundamental rating for CVS stock?
ChartMill assigns a fundamental rating of 4 / 10 to CVS.
What is the valuation status of CVS HEALTH CORP (CVS) stock?
ChartMill assigns a valuation rating of 6 / 10 to CVS HEALTH CORP (CVS). This can be considered as Fairly Valued.
What is the profitability of CVS stock?
CVS HEALTH CORP (CVS) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for CVS stock?
The Earnings per Share (EPS) of CVS HEALTH CORP (CVS) is expected to grow by 7.45% in the next year.
Can you provide the dividend sustainability for CVS stock?
The dividend rating of CVS HEALTH CORP (CVS) is 7 / 10 and the dividend payout ratio is 192.14%.